Effect Of Prostaglandins and Beta Blockers on Progression Of Hypertensive and Normotensive Glaucomas

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21460%2F21%3A00347857" target="_blank" >RIV/68407700:21460/21:00347857 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/21:73605706

Výsledek na webu

<a href="https://doi.org/10.5507/bp.2020.011" target="_blank" >https://doi.org/10.5507/bp.2020.011</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2020.011" target="_blank" >10.5507/bp.2020.011</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect Of Prostaglandins and Beta Blockers on Progression Of Hypertensive and Normotensive Glaucomas

Popis výsledku v původním jazyce

The HTG group included 12 patients (mean age 66 years) with approximately the same changes in the visual field and central corneal thickness (CCT-568 um) treated with prostaglandins, and 12 patients (mean age 60 years, CCT=544 um) treated with beta-blockers. The IOP ranged from 12 to 18 mmHg for the whole follow-up period. The NTG group consisted of three subgroups. The first subgroup consisted of 14 patients (mean age 58 years) who were treated with prostaglandins. The second subgroup consisted of 10 patients (mean age 57 years) who were treated with beta blockers. The third subgroup consisted of 18 patients (mean age 57 years) who underwent no ophthalmological therapy. IOP was within the range of 8-12 mmHg over the whole follow-up period. In all patients, we monitored the pattern defect (PD) and overall defect (OD) within a period of five years. The treatment was not modified during the treatment period. All patients were compensated for cardiovascular status and had no other internal or neurological disease. Visual acuity was 1.0 with a possible correction (less than 3 dioptres) in all patients.There was no statistically significant difference in HTG during the treatment with prostaglandins in PD (P=0.35) and OD (P=0.09) or beta blockers (P=0.37 and 0.23, respectively). In NTG, the greatest changes occurred in PD (P=0.0001) in untreated patients. OD showed no statistically significant changes (P=0.25). Similarly, the patients on prostaglandins had a statistically significant difference in PD (P=0.04), while OD did not show statistically significant changes (P=0.4). We did not find statistically significant differences in progression in patients with NTG treated with beta blockers PD (P=0.7), OD (P=0.4).

Název v anglickém jazyce

Effect Of Prostaglandins and Beta Blockers on Progression Of Hypertensive and Normotensive Glaucomas

Popis výsledku anglicky

The HTG group included 12 patients (mean age 66 years) with approximately the same changes in the visual field and central corneal thickness (CCT-568 um) treated with prostaglandins, and 12 patients (mean age 60 years, CCT=544 um) treated with beta-blockers. The IOP ranged from 12 to 18 mmHg for the whole follow-up period. The NTG group consisted of three subgroups. The first subgroup consisted of 14 patients (mean age 58 years) who were treated with prostaglandins. The second subgroup consisted of 10 patients (mean age 57 years) who were treated with beta blockers. The third subgroup consisted of 18 patients (mean age 57 years) who underwent no ophthalmological therapy. IOP was within the range of 8-12 mmHg over the whole follow-up period. In all patients, we monitored the pattern defect (PD) and overall defect (OD) within a period of five years. The treatment was not modified during the treatment period. All patients were compensated for cardiovascular status and had no other internal or neurological disease. Visual acuity was 1.0 with a possible correction (less than 3 dioptres) in all patients.There was no statistically significant difference in HTG during the treatment with prostaglandins in PD (P=0.35) and OD (P=0.09) or beta blockers (P=0.37 and 0.23, respectively). In NTG, the greatest changes occurred in PD (P=0.0001) in untreated patients. OD showed no statistically significant changes (P=0.25). Similarly, the patients on prostaglandins had a statistically significant difference in PD (P=0.04), while OD did not show statistically significant changes (P=0.4). We did not find statistically significant differences in progression in patients with NTG treated with beta blockers PD (P=0.7), OD (P=0.4).

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30207 - Ophthalmology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers

ISSN

1213-8118

e-ISSN

1804-7521

Svazek periodika

164

Číslo periodika v rámci svazku

March

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

3

Strana od-do

189-191

Kód UT WoS článku

000660244900013

EID výsledku v databázi Scopus

2-s2.0-85100877186